Research note
Tesamorelin: what the evidence check says
A plain-English research note for the reviewed claim: Tesamorelin is proven for general weight loss.
What was reviewed
Tesamorelin is proven for general weight loss.
What the evidence check says
Tesamorelin evidence and labeling support a narrow HIV-associated lipodystrophy context. General weight-loss claims are misleading because the prescribing information says it is not indicated for weight-loss management.
What this does not mean
This note is educational. It does not provide dosing guidance, protocols, buying advice, or personalized medical advice.
Related evidence checks
Related peptides
Sources
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.EGRIFTA SV prescribing information